| 8.56 -0.36 (-4.04%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.44 |
1-year : | 11.34 |
| Resists | First : | 8.94 |
Second : | 9.71 |
| Pivot price | 8.69 |
|||
| Supports | First : | 7.69 |
Second : | 6.4 |
| MAs | MA(5) : | 8.88 |
MA(20) : | 8.54 |
| MA(100) : | 6.5 |
MA(250) : | 5.98 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 50.4 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 9.71 | Low : | 3.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SGHT ] has closed above bottom band by 41.9%. Bollinger Bands are 16.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.99 - 9.04 | 9.04 - 9.08 |
| Low: | 8.37 - 8.42 | 8.42 - 8.48 |
| Close: | 8.46 - 8.55 | 8.55 - 8.63 |
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Mon, 05 Oct 2026
To cover stock-vesting taxes, Sight Sciences (SGHT) CFO sells 7,208 shares under a trading plan. - Stock Titan
Mon, 05 Oct 2026
To cover stock-vesting taxes, Sight Sciences (SGHT) CTO sells 7,797 shares under a trading plan. - Stock Titan
Mon, 05 Oct 2026
Under a trading plan, Sight Sciences (SGHT) CEO sells 29,653 shares to cover stock-vesting taxes. - Stock Titan
Thu, 01 Oct 2026
Sight Sciences, Inc. (SGHT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 01 Oct 2026
A new glaucoma surgery tool aims to lower eye pressure without an implant - Stock Titan
Thu, 01 Oct 2026
Sight Sciences to Debut the OMNI Ultra® Surgical System, - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 55 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 20 (%) |
| Held by Institutions | 52.4 (%) |
| Shares Short | 884 (K) |
| Shares Short P.Month | 830 (K) |
| EPS | -0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.97 |
| Profit Margin | -35.7 % |
| Operating Margin | -16.7 % |
| Return on Assets (ttm) | -10.9 % |
| Return on Equity (ttm) | -48.5 % |
| Qtrly Rev. Growth | 19.5 % |
| Gross Profit (p.s.) | 1.33 |
| Sales Per Share | 1.51 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -15.57 |
| PEG Ratio | 0 |
| Price to Book value | 8.82 |
| Price to Sales | 5.65 |
| Price to Cash Flow | -20.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|